TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

J F Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.